Endothelial dysfunction and regulatory peptides

Cardiovascular diseases, such as acute myocardial infarction or acute cerebrovascular accident, occupy leading positions in the structure of causes of death worldwide. The pathogenesis of these diseases is based on a multifocal lesion of the vascular endothelium, including an abnormal increase in oxidative stress, the development of inflammation, hyperactivity of the renin-angiotensin system, which leads to the development of endothelial dysfunction, and knowledge of pathogenetic application points determines the possibility of rational pharmacotherapy of these diseases. Considering the number of side effects associated with synthetic drugs, there is an increasing interest in bioregulatory peptides as part of complex therapy, which are a source for the development of medicines of natural origin. This review presents data on the potential of peptide bioregulators with antioxidant, anti-inflammatory and modulating renin-angiotensin system (RAS), presents the pharmacodynamic properties of this group of drugs that determine their pharmacodynamic effects. Bioregulatory peptides are a promising direction for the correction of endothelial dysfunction and treatment as part of the complex therapy of diseases that it is based on, based on the modulation of oxidative stress, inflammation and hyperactivity of the RAS.